Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
about
Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance.Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECTA single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis.D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study.BDNF and Huntingtin protein modifications by manganese: implications for striatal medium spiny neuron pathology in manganese neurotoxicity.Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology.Functional imaging in Parkinson's disease and dementia with Lewy bodies.Positron emission tomography imaging of transplant function.How to diagnose MSA early: the role of magnetic resonance imaging.Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.Imaging the head: functional imaging.Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.Glutamate and dopamine in schizophrenia: an update for the 21st centuryInvestigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans.SPECT imaging evaluation in movement disorders: far beyond visual assessment.Prefronto-striatal physiology is associated with schizotypy and is modulated by a functional variant of DRD2Initial clinical experiences with dopamine D2 receptor imaging by means of 2'-iodospiperone and single-photon emission computed tomography.D2-dopamine-receptor occupancy during treatment with haloperidol decanoate.Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade.Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humans.SPECT study of the nigrostriatal dopaminergic system in Huntington's disease.123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease.Dystonia in ataxia telangiectasia: report of a case with putaminal lesions and decreased striatal [123I]iodobenzamide binding.Dopamine D2 receptor blockade and antimigraine action of flunarizine.No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.Severe akinetic syndrome resulting from a bilateral basal ganglia lesion following bone marrow transplantation.Time course of changes in striatal dopamine transporters and D2 receptors with specific iodinated markers in a rat model of Parkinson's disease.Transmembrane signalling systems in the brain of patients with Parkinson's disease.Decrease of D2 receptors indicated by 123I-iodobenzamide single-photon emission computed tomography relates to neurological deficit in treated Wilson's disease.Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies.[123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy.Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration.Striatal D2 receptor binding in sleep bruxism: a controlled study with iodine-123-iodobenzamide and single-photon-emission computed tomography.Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.Dopamine D2 receptor imaging with SPECT using IBZM in 16 patients with Parkinson disease.
P2860
Q33533750-E7EFC5A7-AC39-4C5C-90A4-FCAF22D50C39Q33591417-ACBF0384-7805-4D47-B634-D2E499870E5DQ33733062-C100744E-817C-4091-9323-2057D3FF2366Q33921841-621E865D-00CC-43AE-9B57-3B0E9AE74CAFQ34335511-DA58F141-B6F3-4358-BB66-E2E0E9DC85ACQ34721945-D581E212-980F-4BC1-AF78-04CECA609CB4Q34976214-8E5AC220-5F7F-490E-8EC0-D45CF645ED75Q35024111-F209FBF5-E953-458C-AFE2-122BD69D08D2Q35863417-0B36EF4C-9B7B-450F-A433-4236FD5DF491Q36045402-D48E0A64-9091-421F-8B9F-8A63BEDA90A7Q36183855-76E58E6F-523E-4C5E-A9E1-6E41CD93882FQ36690711-6243230B-1AC3-4596-9A0F-E7846BB35195Q36718204-014FEF02-6F9B-4BCA-B3A3-2FAE2032D0CFQ36941951-999778A5-D5E7-47B5-8892-CA18F40EFAB7Q36992322-22DD5E89-45E1-4240-B9C4-8DE6324E39B7Q37106123-CB570C08-2DFC-48B9-A26E-2F4159352FDAQ37815026-7231CA1A-33B3-4B26-BE30-C1A562F129C9Q41867856-073FBBF8-9377-424B-BD23-7780E0471D24Q42513051-7F207694-DD7F-4360-82D9-4F091C274409Q42657768-833EF145-CDAF-4AC6-8591-9D740DE7CED0Q45076735-8BE17E16-9F6D-47D5-B76F-685F86DBAFC2Q45094155-62D0D938-81AB-4C83-B4F2-F7B80A282B95Q45291180-093E1409-BE61-4895-8A04-C038EFCDE83BQ45305746-7EAEC875-2EA8-492C-8FFE-949AADEDB96FQ48011827-54A57BBA-7FC2-4894-88FA-013BDE225F82Q48096754-BE3EE3EA-09CF-4F17-AEC6-8ED1FD04D0E0Q48114904-4D169E9E-E6B9-4DC6-A06C-8AF16A75F1E1Q48117776-0AEF802B-DDF4-46D4-B59F-0AFA3119CF48Q48198887-58F5F118-AB11-4D9B-83C7-45F0E6397F3FQ48280757-E3ED8ACC-60C1-44D1-80A4-A26872F7DF1EQ48316986-35031F76-F552-40AF-946A-8DDF10CF7F4AQ48399244-87F791B7-29CB-4621-8082-932D049B49F7Q48535724-650D7CE4-073A-408A-935A-0845E670ADE5Q48571590-0B4297FB-CF5E-493F-A958-25824247846FQ48584250-AED8B8F3-B653-460D-B49E-EB22E0C4BD80Q48586216-C0698D80-65FF-47CB-ABCB-95A6E8F22B39Q48827507-A1654E2E-2DCF-4671-89C5-140DCE1BCA16Q48895830-6940A045-7296-4F73-B70E-D0173B575DDBQ49068807-C7C326EC-19E0-4A6E-8830-7968D2A537E1Q52037428-0FA023D6-6B7F-4D76-99AB-618F905EFA05
P2860
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
@en
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
@nl
type
label
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
@en
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
@nl
prefLabel
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
@en
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
@nl
P2093
P2860
P356
P1476
Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders.
@en
P2093
Angelberger P
Küfferle B
P2860
P304
P356
10.1038/JCBFM.1991.53
P577
1991-03-01T00:00:00Z